Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.40 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | PYGM | P11217 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550827 | 0.94 | PYGL (0.44) | PYGLSMYD3CYP51A1 | |
| SCHEMBL1550512 | 0.93 | DRD2 (0.42) | HRH4PYGLPDE10ASMYD3CYP51A1 | |
| SCHEMBL1550154 | 0.92 | HRH4 (0.38) | ALOX15HRH4PDE10ASMYD3 | |
| SCHEMBL1549798 | 0.92 | AR (0.42) | HRH4HRH3PDE10ASMYD3CYP51A1 | |
| SCHEMBL1549669 | 0.89 | HRH4 (0.38) | HRH4HRH3PDE10ASMYD3CYP51A1 | |
| SCHEMBL1550411 | 0.89 | ALOX15 (0.48) | ALOX15HRH4PYGLPYGMSMYD3 | |
| SCHEMBL1549803 | 0.88 | PYGL (0.38) | HRH4PYGLPYGMPDE10ASMYD3 | |
| SCHEMBL1931365 | 0.88 | ALOX15 (0.53) | ALOX15HRH4PYGLPYGMHRH3 | |
| SCHEMBL1550577 | 0.88 | TP53 (0.39) | HRH4PYGLPYGMPDE10ASMYD3 | |
| SCHEMBL1550291 | 0.87 | CYP51A1 (0.42) | HRH4PYGLPYGMHRH3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925857-B1 | USE OF TRPV4 ANTAGONISTS TO AMELIORATE HYDROCEPHALUS AND RELATED MATERIALS AND METHODS | UNIV INDIANA RES & TECH CORP (US) | 2018-02-14 | — | — | EP | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | claimed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | claimed |
| JP-2011529082-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | claimed |
| EP-2312947-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| EP-2312947-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV1 | ALOX15 971/4885HRH4 122/4885PYGL 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.